FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085501381> ?p ?o ?g. }

• W2085501381 endingPage "9" @default.
• W2085501381 startingPage "8" @default.
• W2085501381 abstract "The need and potential benefit of xenotransplantation has been the driving force to identify approaches to eliminate the first immunological barrier, hyperacute rejection. In the early 1990s, Galα(1,3)Gal was identified as the key epitope that had to be removed to prevent natural antibody binding. In view of the fact that the technology was not available to inactivate genes in any animal larger than mice, the hallmark of that time was the transgenic modification of the germ-line of pigs to express human complement regulators (CRP). The challenge for the field was to identify which combination of human CRP would provide optimal xenograft protection. Some of the human complement regulators prevented hyperacute rejection and extended the survival of pig organs in primates to days in unmodified recipients, or up to 5 months if the recipient was heavily immunosuppressed (1–3). The key event that has revived interest and heightened the confidence of the potential success of xenotransplantation was the production of α1,3galactaosyltransferase knockout pigs (GT−/−) (4–6). It was widely anticipated that the production of these knockout pigs would overcome this perceived modest increase provided by expression of CRP and lead to indefinite survival of pig organs. However, similar survival times were observed in the first reports of GT−/− pig-to-primate vascularized organ transplants (7–9). The significant finding however is that hyperacute rejection has indeed been overcome, and thus allows the dissection of the subsequent immunological barriers that need to be addressed and overcome. The well-timed overview by Cooper et al. in this issue of Transplantation focuses on the recent progress in the xenotransplantation using GT−/− pigs (10). They identify thrombotic microangiopathy, seen in rejected GT−/− organs in primates with reduced chronic immunosuppression, as the next phase to be addressed. Seeing that it is not clear if this is dependent on the immune system or due molecular incompatibilities between the pig and primate coagulation system, the authors highlight the novel immunosuppression or approaches to overcome the coagulation dysregulation they consider are required to improve survival outcomes. Above all, the authors clearly express the view that identification of novel pig antigens that are targets for human natural antibodies is a priority for the field. Both the quantity (number) and quality (protein versus carbohydrate) of these antigens need to be elucidated. N-glycolylneuraminic acid is correctly identified as a non-Galα(1,3)Gal antigen that may require attention. However, Galα(1,3)Gal may still be an important epitope in pig-to-human xenotransplantation (11). Galα(1,3)Gal is also synthesized by a second α1,3galactaosyltransferase, iGb3 synthase (12, 13), and low levels of Galα(1,3)Gal has been reported in Gal−/− mice and pigs (13, 14). Furthermore iGb3 has been shown to activate human natural killer T (NKT) cells (15). While it is clear that iGb3 is not involved in hyperacute rejection, as GT−/− pig organs transplanted into either immunosuppressed or nonimmunosuppressed baboons do not undergo hyperacute rejection, the role this lipid plays in xenograft rejection is uncertain. It may be speculated that anti-iGb3 antibodies, either naturally occurring or induced and of higher affinity, may bind to iGb3 on endothelial cells leading to activated, more procoagulant endothelial cells. Alternatively human NKT cells may be activated by iGb3 and mediated xenograft rejection. Another carbohydrate to be considered is N-acetyllactosamine (NAcLac), which at least in Gal−/− mice is expressed at higher levels than wild type mice (16). Human NKRP1A molecules have been shown bind to NAcLAc as well as Galα(1,3)Gal (17); however, it is unclear whether this is of significance to xenograft rejection. Further studies are required to address these possibilities. In summary, the authors have drawn attention to the fact further studies are required to identify non-Gal antigens that may require future gene targeting. These must include exposed or altered carbohydrate. Furthermore modification of pigs for successful xenotransplantation is likely to include not only targeting the coagulation pathway, but judicious breeding of the existing human CRP transgenic pigs onto the Gal−/− background." @default.
• W2085501381 created "2016-06-24" @default.
• W2085501381 creator A5040777973 @default.
• W2085501381 date "2007-07-15" @default.
• W2085501381 modified "2023-10-16" @default.
• W2085501381 title "Gal Knockout Pigs: Any More Carbohydrates?" @default.
• W2085501381 cites W1972357761 @default.
• W2085501381 cites W1973050697 @default.
• W2085501381 cites W1981498160 @default.
• W2085501381 cites W1994581243 @default.
• W2085501381 cites W1997293204 @default.
• W2085501381 cites W2007610991 @default.
• W2085501381 cites W2034509459 @default.
• W2085501381 cites W2057607651 @default.
• W2085501381 cites W2078835422 @default.
• W2085501381 cites W2085878243 @default.
• W2085501381 cites W2101043709 @default.
• W2085501381 cites W2106084836 @default.
• W2085501381 cites W2146092834 @default.
• W2085501381 cites W2150424118 @default.
• W2085501381 cites W2151164793 @default.
• W2085501381 cites W2163649189 @default.
• W2085501381 cites W3115524093 @default.
• W2085501381 doi "https://doi.org/10.1097/01.tp.0000269728.11879.f6" @default.
• W2085501381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17627228" @default.
• W2085501381 hasPublicationYear "2007" @default.
• W2085501381 type Work @default.
• W2085501381 sameAs 2085501381 @default.
• W2085501381 citedByCount "11" @default.
• W2085501381 countsByYear W20855013812020 @default.
• W2085501381 countsByYear W20855013812021 @default.
• W2085501381 crossrefType "journal-article" @default.
• W2085501381 hasAuthorship W2085501381A5040777973 @default.
• W2085501381 hasBestOaLocation W20855013811 @default.
• W2085501381 hasConcept C102230213 @default.
• W2085501381 hasConcept C104317684 @default.
• W2085501381 hasConcept C111684460 @default.
• W2085501381 hasConcept C126322002 @default.
• W2085501381 hasConcept C141035611 @default.
• W2085501381 hasConcept C159654299 @default.
• W2085501381 hasConcept C182704531 @default.
• W2085501381 hasConcept C195616568 @default.
• W2085501381 hasConcept C203014093 @default.
• W2085501381 hasConcept C2777561873 @default.
• W2085501381 hasConcept C2778442404 @default.
• W2085501381 hasConcept C2911091166 @default.
• W2085501381 hasConcept C3018622758 @default.
• W2085501381 hasConcept C54355233 @default.
• W2085501381 hasConcept C71924100 @default.
• W2085501381 hasConcept C86803240 @default.
• W2085501381 hasConceptScore W2085501381C102230213 @default.
• W2085501381 hasConceptScore W2085501381C104317684 @default.
• W2085501381 hasConceptScore W2085501381C111684460 @default.
• W2085501381 hasConceptScore W2085501381C126322002 @default.
• W2085501381 hasConceptScore W2085501381C141035611 @default.
• W2085501381 hasConceptScore W2085501381C159654299 @default.
• W2085501381 hasConceptScore W2085501381C182704531 @default.
• W2085501381 hasConceptScore W2085501381C195616568 @default.
• W2085501381 hasConceptScore W2085501381C203014093 @default.
• W2085501381 hasConceptScore W2085501381C2777561873 @default.
• W2085501381 hasConceptScore W2085501381C2778442404 @default.
• W2085501381 hasConceptScore W2085501381C2911091166 @default.
• W2085501381 hasConceptScore W2085501381C3018622758 @default.
• W2085501381 hasConceptScore W2085501381C54355233 @default.
• W2085501381 hasConceptScore W2085501381C71924100 @default.
• W2085501381 hasConceptScore W2085501381C86803240 @default.
• W2085501381 hasIssue "1" @default.
• W2085501381 hasLocation W20855013811 @default.
• W2085501381 hasLocation W20855013812 @default.
• W2085501381 hasLocation W20855013813 @default.
• W2085501381 hasOpenAccess W2085501381 @default.
• W2085501381 hasPrimaryLocation W20855013811 @default.
• W2085501381 hasRelatedWork W1967110268 @default.
• W2085501381 hasRelatedWork W1975198612 @default.
• W2085501381 hasRelatedWork W2123072911 @default.
• W2085501381 hasRelatedWork W2140699817 @default.
• W2085501381 hasRelatedWork W2287948418 @default.
• W2085501381 hasRelatedWork W2303705009 @default.
• W2085501381 hasRelatedWork W2403005206 @default.
• W2085501381 hasRelatedWork W2410290993 @default.
• W2085501381 hasRelatedWork W2464999925 @default.
• W2085501381 hasRelatedWork W4280594208 @default.
• W2085501381 hasVolume "84" @default.
• W2085501381 isParatext "false" @default.
• W2085501381 isRetracted "false" @default.
• W2085501381 magId "2085501381" @default.
• W2085501381 workType "article" @default.